Format

Send to

Choose Destination
See comment in PubMed Commons below
Pulm Pharmacol Ther. 2013 Oct;26(5):540-3. doi: 10.1016/j.pupt.2013.04.002. Epub 2013 Apr 11.

LABAs in asthmatic children: highlights and new inside.

Author information

1
Department of Pediatrics, Second University of Naples, Naples, Italy. michele.miraglia@unina2.it

Abstract

International asthma guidelines recommend increasing the dose of ICS or adding leukotriene modifiers or the use of long-acting inhaled beta2-agonists (LABAs) in combination with inhaled corticosteroids (ICS) when uncontrolled asthma occurs in adult and children in treatment with low-dose inhaled corticosteroids. However, in children, the effects of this last treatment option are unclear because there are few studies on the efficacy and safety of these drugs in pediatric age. Furthermore, salmeterol is licensed for use in children over 4 years and formoterol in children of more than 6 years. Finally, recent data provides evidence that repeated bronchoconstriction induces epithelial cell stress that may lead to remodeling and these findings may have potential implications for asthma management, particularly for LABAs treatment in the future.

KEYWORDS:

Asthma; Children; LABAs

PMID:
23583567
DOI:
10.1016/j.pupt.2013.04.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center